Chart Events
Performance Outlook
| Previous Close | 9.88 |
| Open | 10.26 |
| Bid | 0.00 x N/A |
| Ask | 10.08 x N/A |
| Day's Range | 9.88 - 9.88 |
| 52 Week Range | 9.88 - 9.88 |
| Volume | 225 |
| Avg. Volume | N/A |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Targovax ASA: Exercise of options under LTI program and resolution to increase the share capital
The board of directors of Targovax ASA (OSE:TRVX) ("Targovax" or the "Company") has resolved to increase the share capital of the Company following the completion of an exercise period for vested share options under the Company's long-term incentive program for employees. The exercise period for the LTI program commenced on 19 February 2021 at 10:00 hours (CET) and ended on 1 March 2021 at 10:00 hours (CET).
- PR Newswire
Continued survival benefit in Targovax's ONCOS-102 trial in mesothelioma at the 21-month follow-up
Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces 21-month follow-up data from the randomized phase I/II trial of ONCOS-102 in combination with standard of care chemotherapy in malignant pleural mesothelioma (MPM).
- PR Newswire
Targovax receives Fast-Track designation for ONCOS-102
Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that its lead clinical candidate ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the US FDA.
